Davita Healthcare Partners DVA

$183.64 -2.46 (-1.32%)

Valuation

Market cap
11,280,476,000
Revenue TTM
$13,643,070,000
Net income TTM
$746,800,000
PE ratio
13.70
Forward PE
12.03
Profit margin
5.47%
Debt to equity
-22.44

Trading

Volume
618,097
Avg volume
661,344
Day's range
$183.46 – $187.52
Shares out
63,800,000
Stochastic %K
75%
Beta
0.80
Analysts
Sell
Price target
$223.43

Price

Company profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other phys...

Show more

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Industry
Medical Care Facilities
Sector
Healthcare
Phone
720 631 2100
Website
https://www.davita.com
Address
2000 16th Street, Denver, United States

Latest news

Stocktwits

REZZAYO Oct 23, 4:49 PM
$CRMD In plain English Defencath Proven to be: -Per Patient per Year pre Defencath Acquisition and related Costs 1- Saved $185.24 relates to Avoided CRBSI hospitalizations costs that otherwise would be beared by Both Medicare Part A+B (FFS) & Medicare Part C (MAs ≈ $UNH $HUM CVS Elevance, Clover) 2- Saved $130.84 relates to Avoided alteplase medication costs that otherwise would be beared by $DVA $FMS USRC IRC 3- Caused $55.37 of Additional revenue from recovered dialysis sessions that otherwise would be missed by Davita, Fresenius, USRC, IRC
1 replies
peloswing Oct 23, 4:20 PM
$DVA $553,000+ on Jan. 19th 2029 $195 calls Also $30K+ on the Jan. 19th 2029 $220 calls OTM, dated bets
1 replies
Gencooliveoil Oct 22, 12:16 PM
$AKBA $CRMD $DVA $FMS
0 replies
Noname2022 Oct 22, 1:34 AM
$AKBA $CRMD $DVA $FMS
0 replies
hitmongreen Oct 20, 7:48 PM
$DVA what's going on here?
0 replies
Small_time_trader Oct 20, 7:17 PM
$DVA $FMS https://www.gurufocus.com/news/9132369/hhs-launches-kidney-care-national-plan-impacting-davita-inc-dva-outlook No real details on what will lower barrier of entry into dialysis care. Just lower “regulations”. No matter what this space is not easy to get into, you also need scale.
0 replies
RAstx Oct 20, 6:38 PM
$DVA https://www.gurufocus.com/news/9132301/davita-dva-shares-slip-amid-trump-administration-dialysis-market-competition-push
0 replies
Following_the_trend Oct 20, 4:10 PM
$DVA Big dip
1 replies